Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products

Drug Profile

Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products

Alternative Names: 4-HPR/LXS; Fenretinide LYM-X-SORB; HPR/LXS; LXS/4-HPR

Latest Information Update: 19 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biomolecular Products; Lym-Drug Products LLC
  • Developer Academic Medical Center; Childrens Hospital Los Angeles; National Cancer Institute (USA)
  • Class Antineoplastics; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Insulin resistance
  • Phase I Lymphoma; Neuroblastoma; Solid tumours

Most Recent Events

  • 19 Jan 2016 Phase-II development for Insulin resistance is ongoing in Netherlands
  • 01 May 2014 Phase-I clinical trials in Neuroblastoma (combination therapy, recurrent) in USA (PO) (NCT02163356)
  • 13 Mar 2014 Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products is available for licensing as of 13 Mar 2014. http://www.biomolecularproducts.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top